Elekta introduces Venezia, a new option for treating advanced stage cervical cancer at World Congress of Brachytherapy
Offers clinicians an intuitive and versatile tool for optimizing patient care
At the World Congress of Brachytherapy, June 27 – 29 in San Francisco, Elekta (booth #401) will introduce Venezia, a new option for treating advanced stage cervical cancer. Venezia is an advanced gynecological applicator that provides clinicians with improved access to stage IIIA, IIIB and IVA tumors in the cervix, parametrium and vaginal extensions.
Venezia allows clinicians to treat advanced stage cervical tumors that previously required specialized techniques such as free-hand needle placement. The applicator offers an easy way to reach tumors through a combination of straight and oblique needles with reproducible and consistent needle placement.
“Treating advanced stage cervical cancer has historically been challenging because many existing brachytherapy applicators could not always reach the tumor,” said Ben Pais, Vice President Medical Affairs, Elekta. “With a patented snap-fit design, Venezia reduces the complexity of treating advanced stage cervical cancer and shortens implantation time in the operating room. Venezia is a versatile and intuitive clinical tool that is also well suited for treating earlier stage disease.”
“With its hybrid brachytherapy applicator, Venezia combines the best characteristics of both ring and ovoid devices,” noted Richard Pötter, MD, Professor and Head of the Department of Radiation Oncology at the Medical University of Vienna, and one of Venezia’s developers. “With Venezia, we expect to realize the benefits of the ovoid’s simple applicability and the ring applicator’s reproducible dose distribution, which allows predictable radiation delivery into the proximal and distal parametria. Venezia has the potential to become a universal applicator for use in treatment of cervical cancer as well as cancers in the uterus and the vagina.”
To learn more about Venezia, visit: https://wavelength.elekta.com/2016/04/new-brachytherapy-applicator-expands-reach-of-gyn-cancer-treatment/.
Venezia is not available for sale or distribution in all markets and is not for sale in the United States and is pending 510(k) clearance.
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524, e-mail: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.